These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 32544184)

  • 1. Higher naloxone dosing in a quantitative systems pharmacology model that predicts naloxone-fentanyl competition at the opioid mu receptor level.
    Moss RB; Pryor MM; Baillie R; Kudrycki K; Friedrich C; Reed M; Carlo DJ
    PLoS One; 2020; 15(6):e0234683. PubMed ID: 32544184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effects of Intramuscular Naloxone Dose on Mu Receptor Displacement of Carfentanil in Rhesus Monkeys.
    Scott PJH; Koeppe RA; Shao X; Rodnick ME; Sowa AR; Henderson BD; Stauff J; Sherman PS; Arteaga J; Carlo DJ; Moss RB
    Molecules; 2020 Mar; 25(6):. PubMed ID: 32192089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noradrenergic Mechanisms in Fentanyl-Mediated Rapid Death Explain Failure of Naloxone in the Opioid Crisis.
    Torralva R; Janowsky A
    J Pharmacol Exp Ther; 2019 Nov; 371(2):453-475. PubMed ID: 31492824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose naloxone formulations are not as essential as we thought.
    Lemen PM; Garrett DP; Thompson E; Aho M; Vasquez C; Park JN
    Harm Reduct J; 2024 May; 21(1):93. PubMed ID: 38741224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a Translational Model to Assess the Impact of Opioid Overdose and Naloxone Dosing on Respiratory Depression and Cardiac Arrest.
    Mann J; Samieegohar M; Chaturbedi A; Zirkle J; Han X; Ahmadi SF; Eshleman A; Janowsky A; Wolfrum K; Swanson T; Bloom S; Dahan A; Olofsen E; Florian J; Strauss DG; Li Z
    Clin Pharmacol Ther; 2022 Nov; 112(5):1020-1032. PubMed ID: 35766413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prepacked naloxone administration for suspected opioid overdose in the era of illicitly manufactured fentanyl: a retrospective study of regional poison center data.
    Mahonski SG; Leonard JB; Gatz JD; Seung H; Haas EE; Kim HK
    Clin Toxicol (Phila); 2020 Feb; 58(2):117-123. PubMed ID: 31092050
    [No Abstract]   [Full Text] [Related]  

  • 7. Higher naloxone dosing may be required for opioid overdose.
    Bardsley R
    Am J Health Syst Pharm; 2019 Oct; 76(22):1835-1837. PubMed ID: 31665765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sentanyl: a comparison of blood fentanyl concentrations and naloxone dosing after non-fatal overdose.
    Krotulski AJ; Chapman BP; Marks SJ; Ontiveros ST; Devin-Holcombe K; Fogarty MF; Trieu H; Logan BK; Merchant RC; Babu KM
    Clin Toxicol (Phila); 2022 Feb; 60(2):197-204. PubMed ID: 34278904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of naloxone nasal spray 4 mg in the community setting: a survey of use by community organizations.
    Avetian GK; Fiuty P; Mazzella S; Koppa D; Heye V; Hebbar P
    Curr Med Res Opin; 2018 Apr; 34(4):573-576. PubMed ID: 28535115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study.
    McDonald R; Lorch U; Woodward J; Bosse B; Dooner H; Mundin G; Smith K; Strang J
    Addiction; 2018 Mar; 113(3):484-493. PubMed ID: 29143400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fentanyl causes naloxone-resistant vocal cord closure: A platform for testing opioid overdose treatments.
    Miner NB; Schutzer WE; Zarnegarnia Y; Janowsky A; Torralva R
    Drug Alcohol Depend; 2021 Oct; 227():108974. PubMed ID: 34492557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overdoses due to fentanyl and its analogues (F/FAs) push naloxone to the limit.
    Pergolizzi JV; Dahan A; Ann LeQuang J; Raffa RB
    J Clin Pharm Ther; 2021 Dec; 46(6):1501-1504. PubMed ID: 34111307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher doses of naloxone are needed in the synthetic opiod era.
    Moss RB; Carlo DJ
    Subst Abuse Treat Prev Policy; 2019 Feb; 14(1):6. PubMed ID: 30777088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of rates of opioid withdrawal symptoms and reversal of opioid toxicity in patients treated with two naloxone dosing regimens: a retrospective cohort study.
    Purssell R; Godwin J; Moe J; Buxton J; Crabtree A; Kestler A; DeWitt C; Scheuermeyer F; Erdelyi S; Balshaw R; Rowe A; Cochrane CK; Ng B; Jiang A; Risi A; Ho V; Brubacher JR
    Clin Toxicol (Phila); 2021 Jan; 59(1):38-46. PubMed ID: 32401548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal naloxone rapidly occupies brain mu-opioid receptors in human subjects.
    Johansson J; Hirvonen J; Lovró Z; Ekblad L; Kaasinen V; Rajasilta O; Helin S; Tuisku J; Sirén S; Pennanen M; Agrawal A; Crystal R; Vainio PJ; Alho H; Scheinin M
    Neuropsychopharmacology; 2019 Aug; 44(9):1667-1673. PubMed ID: 30867551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies on the abstinence-like overshoot following reversal of the potent 19-isoamyl derivative of etorphine with naloxone. A comparison with the opioids fentanyl and alfentanil.
    Freye E; Neruda B; Smith OW
    Arzneimittelforschung; 1997 Jan; 47(1):6-9. PubMed ID: 9037435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of take-home naloxone in the epidemic of opioid overdose involving illicitly manufactured fentanyl and its analogs.
    Kim HK; Connors NJ; Mazer-Amirshahi ME
    Expert Opin Drug Saf; 2019 Jun; 18(6):465-475. PubMed ID: 31033357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of a novel, approved, 1.4-mg intranasal naloxone formulation for reversal of opioid overdose-a randomized controlled trial.
    Skulberg AK; Åsberg A; Khiabani HZ; Røstad H; Tylleskar I; Dale O
    Addiction; 2019 May; 114(5):859-867. PubMed ID: 30644628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naloxone dosing in the era of ultra-potent opioid overdoses: a systematic review.
    Moe J; Godwin J; Purssell R; O'Sullivan F; Hau JP; Purssell E; Curran J; Doyle-Waters MM; Brasher PMA; Buxton JA; Hohl CM
    CJEM; 2020 Mar; 22(2):178-186. PubMed ID: 31955714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opioid Antagonists from the Orvinol Series as Potential Reversal Agents for Opioid Overdose.
    Disney A; Olson KM; Shafer AM; Moore SC; Anand JP; Traynor JR; Husbands SM
    ACS Chem Neurosci; 2022 Nov; 13(21):3108-3117. PubMed ID: 36223082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.